Can I Take Melatonin with AOD-9604?

What Is AOD-9604 and Why Does the Combination Matter?

AOD-9604 is a synthetic peptide representing amino acids 176 to 191 of human growth hormone (HGH), modified with a tyrosine residue at its N-terminus. Unlike full-length HGH, it does not bind the classical GH receptor in a way that raises IGF-1 significantly, but preclinical data suggest it activates beta-3 adrenergic receptor pathways to stimulate lipolysis and inhibit lipogenesis [1]. That metabolic specificity is exactly why prescribers using 503A compounding pharmacies have paired it with other agents aimed at body composition.

Melatonin is the most widely self-administered sleep supplement in the United States. A 2022 NHANES-linked analysis estimated that approximately 6.1 million U.S. Adults take more than 5 mg nightly, a fourfold increase from 1999 [2]. Because melatonin receptors are expressed in pancreatic beta cells and adipose tissue, the metabolic overlap with AOD-9604 is not trivial.

How AOD-9604 Works at the Cellular Level

The peptide binds beta-3 adrenergic receptors on adipocytes, triggering cyclic AMP production that activates hormone-sensitive lipase. A 12-week, placebo-controlled trial in obese adults (N=300) published in Obesity Research found that oral AOD-9604 at 1 mg/kg/day produced statistically significant fat loss without altering fasting glucose or IGF-1 [1]. That glucose neutrality is a key reference point when evaluating what melatonin adds to the picture.

How Melatonin Works in Metabolic Tissue

Melatonin's primary sleep-promoting action flows through MT1 receptors in the suprachiasmatic nucleus, but MT1 and MT2 receptors in pancreatic islets suppress nocturnal insulin secretion to keep blood glucose from dropping during sleep. The journal Diabetologia published a large Mendelian randomization study (N=107,136) showing that genetic variants near MTNR1B that raise nocturnal melatonin levels associate with higher fasting glucose and a 3-fold increased type 2 diabetes risk [3]. Supplemental melatonin at doses above 5 mg may mimic this effect acutely.

Is There a Direct Pharmacokinetic Interaction?

No evidence currently supports a direct pharmacokinetic interaction, meaning neither compound appears to alter the absorption, distribution, metabolism, or excretion of the other. AOD-9604 is a peptide administered subcutaneously; it is cleaved by serum proteases with a plasma half-life estimated at roughly 10 to 20 minutes before its active fragments distribute to adipose tissue [4]. Melatonin is absorbed orally, metabolized by hepatic CYP1A2 to 6-sulfatoxymelatonin, and cleared with a half-life of 40 to 60 minutes [5].

CYP Enzyme Overlap

AOD-9604 is not a CYP substrate. Melatonin is primarily a CYP1A2 substrate. That means fluvoxamine or ciprofloxacin could raise melatonin levels dramatically, but AOD-9604 does not use that enzymatic pathway. No competitive inhibition or induction is expected between these two compounds.

Protein Binding Considerations

Melatonin is approximately 60% protein-bound. AOD-9604, as a small peptide (molecular weight roughly 1,815 Da), does not compete for albumin binding sites in a clinically meaningful way. Displacement interactions are not a concern here.

The Pharmacodynamic Overlap: Where the Real Risk Lives

This is where clinical thinking must be more careful. Both compounds touch glucose homeostasis and fat metabolism, and their effects may add together in ways that neither compound produces alone.

Melatonin's Effect on Insulin Secretion

Melatonin suppresses glucose-stimulated insulin secretion. A double-blind crossover trial (N=21 healthy adults) published in the Journal of Clinical Endocrinology and Metabolism found that a single 4 mg oral melatonin dose taken before an oral glucose tolerance test impaired insulin secretion and raised peak glucose area-under-curve by 12% compared to placebo [6]. The effect was more pronounced in MTNR1B G-allele carriers.

Higher OTC doses (5 to 10 mg) common in the U.S. Market could produce a more pronounced glucose blunting of insulin response, particularly when combined with any agent, like AOD-9604, that is independently modulating fatty acid flux. Elevated non-esterified fatty acids from AOD-9604-driven lipolysis can reduce peripheral insulin sensitivity through diacylglycerol-mediated protein kinase C activation. The two effects do not necessarily cancel each other; they may compound.

Lipolysis and the Overnight Metabolic Window

AOD-9604 is typically injected either first thing in the morning (fasted) or 30 to 60 minutes before bed to coincide with the natural nocturnal growth hormone pulse. Evening injection timing directly overlaps with when most people take melatonin. That overlap is the scenario that warrants the most scrutiny.

During the nocturnal period, melatonin suppresses insulin, while AOD-9604 may continue to drive lipolysis. Free fatty acid elevation overnight has been associated with morning insulin resistance in metabolic studies. A 2020 review in Frontiers in Endocrinology summarized evidence that elevated nocturnal free fatty acids predict next-morning fasting glucose increments in individuals with metabolic syndrome [7].

Who Is Most Affected?

People with prediabetes, insulin resistance, polycystic ovary syndrome, or known MTNR1B G-allele carrier status carry a higher risk profile for this pharmacodynamic overlap. In those individuals, the combination of suppressed nocturnal insulin and increased lipolytic flux could meaningfully raise fasting glucose over weeks of nightly use.

Practical Dose-Separation and Timing Guidance

The following timing framework is based on each compound's known pharmacokinetic profile and is designed to reduce the window of overlap between peak melatonin activity and active AOD-9604 lipolytic signaling.

Morning AOD-9604 Protocol

If injecting AOD-9604 in the morning (the most common approach), melatonin taken at bedtime 12 or more hours later carries essentially zero overlap. This is the lowest-risk timing configuration. Subcutaneous AOD-9604 peaks in tissue within approximately 30 minutes and its active lipolytic signaling dissipates within 2 to 4 hours, well before a nighttime melatonin dose [4].

Evening AOD-9604 Protocol

If your prescriber has you injecting AOD-9604 at night before sleep, observe a minimum 30-minute gap before taking melatonin. A 60-minute gap is preferable in anyone with metabolic risk factors. Keep melatonin at the lowest effective dose, which is typically 0.5 to 1 mg for sleep onset, not the 5 to 10 mg doses common in U.S. Retail products. The American Academy of Sleep Medicine's 2023 clinical practice guideline on chronic insomnia does not recommend doses above 0.5 mg for circadian phase-shifting because higher doses produce no additional benefit and increase morning carryover [8].

Dose Capping Recommendation

Use melatonin at or below 1 mg when combining with any agent that modulates nocturnal lipolysis or insulin signaling. A 0.5 mg sublingual formulation achieves plasma levels sufficient for sleep onset (roughly 300 pg/mL serum) without the pronounced beta-cell suppression seen at doses above 3 mg [5].

Monitoring Protocol When Using Both Compounds

Routine metabolic monitoring is the most practical safety tool here, since no specific antidote exists for a pharmacodynamic interaction and no validated severity scale has been published for this combination.

Baseline Labs Before Starting the Combination

• Fasting glucose
• Fasting insulin and HOMA-IR calculation
• HbA1c
• Fasting lipid panel (to document baseline free fatty acid metabolism status)
• If clinically appropriate, consider MTNR1B genotyping through a panel that includes rs10830963

Follow-Up Monitoring Schedule

Repeat fasting glucose and insulin at 6 weeks and 12 weeks after initiating the combination. A fasting glucose rise of more than 10 mg/dL from baseline in the absence of dietary changes should prompt a clinical review and possible melatonin dose reduction or timing shift to morning.

HbA1c at 12 weeks will capture any chronic glycemic drift. A rise of 0.3% or more warrants stopping one of the two agents and reassessing.

Symptom Signals Worth Reporting

Morning headaches, excessive daytime sleepiness, or polyuria could indicate either excessive melatonin carryover or subclinical glucose dysregulation, respectively. Neither symptom cluster is specific, but both are worth documenting and discussing with the prescribing clinician.

Special Populations

Individuals with Type 2 Diabetes or Prediabetes

This combination requires extra caution. A meta-analysis of 23 randomized trials (N=1,654) found that melatonin supplementation significantly worsened glycemic control in individuals with type 2 diabetes, raising fasting glucose by a mean of 3.3 mg/dL and HbA1c by 0.09% at doses of 2 to 10 mg [9]. AOD-9604's lipolytic activity in this population may further tax beta-cell reserve. If a prescriber deems the combination appropriate, starting melatonin at 0.3 mg is prudent and glucose self-monitoring before bed and upon waking adds a practical safety layer.

Women with PCOS

Women with polycystic ovary syndrome often have underlying insulin resistance and elevated nocturnal LH-pulse amplitude. AOD-9604 is sometimes discussed in this context for its potential body-composition effects, though no PCOS-specific RCT exists. Melatonin has independently shown some benefit in PCOS by reducing oxidative stress. A randomized trial (N=40) published in Gynecological Endocrinology found 6 mg melatonin over 12 weeks improved antioxidant markers in PCOS without significant glycemic change at that dose [10]. Nonetheless, the concurrent use of lipolytic peptides and melatonin in this population has not been studied, so individual glucose monitoring is warranted.

Older Adults

CYP1A2 activity declines with age, which means melatonin clearance slows in adults over 65. Peak serum melatonin levels after a 5 mg dose can be 10-fold higher in a 70-year-old compared to a 30-year-old [5]. Older adults using AOD-9604 for body composition should keep melatonin at 0.3 to 0.5 mg and avoid evening peptide injection timing unless under close metabolic supervision.

What the Regulatory and Compounding Field Means for You

AOD-9604 is not FDA-approved as a drug. It was removed from the FDA's bulk substances list used for 503B compounding pharmacies in 2015, but it may still be compounded under 503A for individual patients with a valid prescription [11]. Melatonin is classified as a dietary supplement under DSHEA and is not subject to pre-market FDA approval.

Because neither compound has gone through the full NDA approval pathway as a combination product, no official FDA-approved label interaction warning exists for this pairing. That regulatory silence does not imply safety. It reflects the absence of commercial incentive to run combination trials on compounds that cannot be jointly patented.

What "Research/503A" Status Means Practically

Prescribers ordering AOD-9604 through a 503A pharmacy are working within a legal but off-label framework. The responsibility for monitoring interactions with non-prescription supplements like melatonin falls entirely on the prescribing clinician and the patient. Documenting informed consent to that monitoring responsibility is good clinical practice.

What to Do If You Are Already Taking Both

If you are currently taking melatonin alongside AOD-9604 and have not experienced any glucose symptoms or morning hyperglycemia, that is reassuring. The interaction risk is rated low-to-moderate for most metabolically healthy adults. Several practical steps are worth taking:

First, confirm your melatonin dose. Many OTC products contain 5 mg or 10 mg, far above what physiology requires. Switching to a 0.5 mg or 1 mg formulation reduces the beta-cell suppression window without sacrificing sleep quality for most users.

Second, time your AOD-9604 injection to the morning if your prescriber approves. That single change eliminates virtually all timing overlap with a bedtime melatonin dose.

Third, get a fasting glucose drawn if you have not had one in the past 3 months. A value above 100 mg/dL warrants a conversation with your prescriber about whether the evening timing of AOD-9604 is still appropriate.

Fourth, report any new onset of excessive morning hunger, fatigue, or blurred vision immediately. These are non-specific but could indicate glycemic variability worth investigating.

A Note on Evidence Quality

The honest clinical picture here is that no published human trial has examined AOD-9604 and melatonin in combination. The guidance above is based on each compound's independently established pharmacology, mechanism-based extrapolation, and the clinical principle of minimizing overlapping pharmacodynamic effects on shared metabolic pathways. That is the standard approach used in the absence of direct combination data, and it aligns with how FDA guidance documents on drug-supplement interactions recommend clinicians proceed [12].

"When direct combination data are unavailable, clinicians should characterize each agent's pharmacodynamic profile individually and apply conservative dosing and monitoring strategies proportional to the patient's baseline metabolic risk," according to the FDA's 2020 guidance on evaluating drug-drug interactions for regulatory submissions [12].